This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:


peer-reviewed publication

trusted source


Possible genetic basis and mouse model found for severe nonalcoholic fatty liver disease

Possible genetic basis and mouse model found for severe nonalcoholic fatty liver disease
The SRSF1 gene acts as a guardian against DNA damage in the liver, University of Illinois Urbana-Champaign researchers found. When it is missing or inactivated, severe nonalcoholic fatty liver disease symptoms develop. Credit: Michael Vincent

A mutant or damaged gene may be a cause of a severe, mysterious form of nonalcoholic fatty liver disease, University of Illinois Urbana-Champaign researchers have found. Mice and human liver cells lacking the SRSF1 gene show all the hallmarks of nonalcoholic steatohepatitis, also known as NASH, the researchers discovered.

The unique mouse model captures all three hallmarks of excess fat, inflammation and scarring in the liver, opening the doors to better understanding and development of treatments for NASH, said study leader Auinash Kalsotra, a biochemistry professor at Illinois. The researchers published their results in the journal Nature Communications.

Nonalcoholic fatty affects an estimated 25% of Americans, according to the National Institutes of Health, and up to a third of patients will develop inflammation and scarring as well, falling under the NASH classification.

"It's not really clear why certain people end up developing NASH," Kalsotra said. "So far, there haven't been any genes that have been directly linked to NASH. It's been thought of as a progression: After the liver is injured or it becomes fatty, if you don't check it, it's going to progress toward NASH. But not everybody with develops NASH and it seems random who does, so it's very confusing as to why this happens."

The other problem making NASH research difficult is the lack of good animal or cellular models for it, Kalsotra said. While some models incorporate one or two of the symptoms, and then other damage inflicted to mimic what is seen in NASH patients, they don't give an accurate portrayal of the disease.

Kalsotra's group began studying SRSF1, a protein that assists in splicing RNA in the cell, to study its splicing activity. They bred a line of mice that were lacking the gene to learn about its splicing activity. The mice soon spontaneously developed all the symptoms of NASH.

"We were very excited to see this, as we thought, this could be a model for the disease. But first, we had to figure out the mechanisms of why SRSF1 was connected to liver disease," said graduate student Waqar Arif, the first author of the study.

Possible genetic basis and mouse model found for severe nonalcoholic fatty liver disease
Gene expression signatures in SRSF1 HKO hepatocytes transition from an early inflammatory to a late fibrotic phase. a) Overlap of differentially expressed genes from RNA-seq (FDR < 0.05, Wald test as described DESeq2; |Log2(Fold Change)| ≥ 1) in 10-day (early) and 1-month (late) old SRSF1 HKO hepatocytes (n = 2 samples/condition). b) Scatter plot showing the distribution of mRNA abundance fold changes in SRSF1 HKO with respect to controls at both early and late timepoints. c) Gene ontology (GO) terms of upregulated and downregulated genes in SRSF1 HKO hepatocytes at 10-day and 1 month or early and late, respectively. d) Bar plot of fold change values determined from RNA-seq analysis for genes involved in inflammation and fibrosis at both early (yellow bars) and late (red bars) timepoints (n = 2 samples per group per timepoint). The error bars represent the associated standard error estimated by DESeq2. The color of gene labels signifies significant upregulation in mRNA abundance at 10-day only (yellow), 1-month only (red), or both (blue). Source data are provided as a Source Data file. Credit: Nature Communications (2023), 10.1038/s41467-023-35932-3

The researchers found that the mechanism was not related to SRSF1's splicing activity, as first thought, but because it protected against DNA damage in the liver during the process of DNA unwinding so its code could be transcribed into RNA. Without the SRSF1 protein, began to shut down.

"What happened was the cell wanted to die because of the extensive damage that was happening to the DNA. But it didn't have the energy for regular programmed cell death processes. The damage was so severe that everything just shut down," said Kalsotra, who also is affiliated with the Carl R. Woese Institute of Genomic Biology and the Cancer Center at Illinois.

It was the opposite of the pathway that had been assumed, Kalsotra said. Instead of excess fat leading to cell damage, the cell damage came first, and fat built up as a result of the cells not being able to perform their function of packaging up digested fats. Inflammation increased as the tried to clear away dead and dying cells, and then fibrosis appeared as scars formed over patches of dead tissue to try to hold the liver together. The researchers saw this same sequence in both the mice without SRSF1 and in human liver cell lines depleted of SRSF1.

"These findings tell us that the genome of the liver cells has to be properly maintained," Kalsotra said. "Liver cells are encountering toxins and DNA damage more than any other cells in our body. This study illustrates that when liver cells encounter excessive DNA damage, these NASH symptoms develop. SRSF1 plays a protective role against that. It acts as a guardian of the liver genome."

The researchers hope the mice will aid other researchers studying NASH, both in terms of understanding the disease and in exploring potential treatment targets.

"We want to see whether there are certain conditions where SRSF1 has been inactivated in some way in human livers or other animals," Kalsotra said. "Maybe there are some toxins or medicines or other environmental pollutants, for example, that could cause inactivation of the SRSF1 gene. Figuring out the triggers that cause silencing of SRSF1 could point to treatment targets, and whether things like anticancer drugs that prevent DNA damage could be applied here. It's interesting to note that many NASH patients develop cancer as well. Is that linked to the DNA damage?"

The researchers also plan to explore whether other genes protect DNA in this way, and whether damage to any of them could cause NASH pathology as well.

More information: Wagar Arif et al, Splicing factor SRSF1 deficiency in the liver triggers NASH-like pathology and cell death, Nature Communications (2023). DOI: 10.1038/s41467-023-35932-3.

Journal information: Nature Communications

Citation: Possible genetic basis and mouse model found for severe nonalcoholic fatty liver disease (2023, February 9) retrieved 2 June 2023 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Liver cells that intensify the progression of nonalcoholic fatty liver disease isolated


Feedback to editors